Literature DB >> 6420517

DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.

W Birkmayer, G Birkmayer, H Lechner, P Riederer.   

Abstract

Parkinsonian patients with orthostatic hypotension and dizziness due to usual antiparkinson therapy have been treated with the precursor amino-acid of noradrenaline, DL-3,4-threo-dihydroxyphenylserine (DL-3,4-threo-DOPS). Oral and intravenous administration improved these side effects significantly. A combined treatment of L-dopa, peripheral decarboxylase inhibitor and DL-3,4-threo-DOPS seems to be of benefit with respect to akinesia and orthostatic hypotension.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6420517     DOI： 10.1007/bf01252816

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  20 in total

1.  Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.

Authors:  P Riederer; W Birkmayer; D Seemann; S Wuketich
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

2.  Cardiovascular actions of bromocriptine.

Authors:  B J Clark; G Scholtysik; E Flückiger
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1978

3.  Participation of central noradrenergic neurons in arterial baroreceptor reflexes in the rabbit. A study with intracisternally administered 6-hydroxydopamine.

Authors:  J P Chalmers; J L Reid
Journal:  Circ Res       Date:  1972-11       Impact factor: 17.367

4.  Levodopa, Parkinson's disease, and hypotension.

Authors:  F H McDowell; J E Lee
Journal:  Ann Intern Med       Date:  1970-05       Impact factor: 25.391

5.  Vascular effects of bromocriptine in the hindlimb of the dog [proceedings].

Authors:  M G Bogaert; W A Buylaert; A F De Schaepdryver; J L Willems
Journal:  Br J Pharmacol       Date:  1978-06       Impact factor: 8.739

6.  Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.

Authors:  T Nagatsu; T Kato; Y Numata; K Ikuta; M Sano
Journal:  Clin Chim Acta       Date:  1977-03-01       Impact factor: 3.786

7.  Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis.

Authors:  P Riederer; W D Rausch; W Birkmayer; K Jellinger; W Danielczyk
Journal:  J Neural Transm Suppl       Date:  1978

8.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15

9.  Increase in noradrenaline-synthesizing enzyme activity in medulla oblongata in Parkinson's disease.

Authors:  N Kopp; L Denoroy; M Tommasi; N Gay; G Chazot; B Renaud
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

10.  Dopamine and noradrenaline levels in peripheral tissues of several mammalian species.

Authors:  C Bell; J S Gillespie
Journal:  J Neurochem       Date:  1981-02       Impact factor: 5.372
View more
  7 in total

1.  Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

Review 2.  Amine precursor amino acid therapy: from neurochemical basis to clinical aspects.

Authors:  T Nakajima
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

3.  Acute pandysautonomia: mass spectrometric and histopathological studies of the sympathetic nervous system during long term L-threo-3,4-dihydroxyphenylserine treatment.

Authors:  M Ushiyama; S Ikeda; T Suzuki; M Yazawa; N Yanagisawa; S Tsujino
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

4.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

5.  Is there room for non-dopaminergic treatment in Parkinson disease?

Authors:  Abraham Lieberman; Narayanan Krishnamurthi
Journal:  J Neural Transm (Vienna)       Date:  2012-12-16       Impact factor: 3.575

Review 6.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

7.  Memory effect of DL-threo-3,4-dihydroxyphenylserine (DOPS) in human Korsakoff's disease.

Authors:  P J Langlais; R G Mair; P J Whalen; W McCourt; W J McEntee
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.